The GLP-1 hair loss comprehensive guide provides broader context across the entire GLP-1 agonist class
As you know, obesity is associated with numerous comorbidities, including type 2 diabetes, cardiovascular diseases, dyslipidemia, hypertension, several forms of cancer, and many more
To note, with the G-agonists, GIP receptors in the brain may respond differently than those peripherally, with less GI side effects
Neither is definitively better the preclinical literature frames them as complementary
(1996): Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study
It is a vicious cycle that semaglutide alone cannot break